Welcome to our dedicated page for Pharma-Bio Serv SEC filings (Ticker: PBSV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pharma-Bio Serv filings document formal disclosures for a consulting firm serving regulated life-science and allied product industries. Its Form 8-K reports furnish operating results and financial-condition updates through earnings releases, while definitive proxy materials cover annual meeting matters, director elections, stockholder voting procedures, board governance and independent auditor ratification. The filings also reflect the company’s public reporting framework for an OTCQB-traded issuer.
Pharma-Bio Serv, Inc. reported higher revenue and profit for the quarter ended April 30, 2026. Revenue for the three and six months was approximately $2.7 million and $5.0 million, up about $0.3 million and $0.1 million from the same periods last year.
Net income for the three and six months reached approximately $0.2 million and $0.3 million, increases of about $0.1 million and $0.2 million year over year. Management highlighted stronger profitability driven by focusing on higher-opportunity markets and maintaining disciplined cost control and operational efficiency.
Pharma-Bio Serv, Inc. reported modest growth and stronger profitability for the quarter and six months ended April 30, 2026. Revenue reached $2.7 million for the quarter and $5.0 million for six months, up slightly from the prior year as Puerto Rico and Europe offset softer U.S. consulting activity.
Net income rose to $233,000 for the quarter and $266,000 for six months, an increase of approximately $0.1 million and $0.2 million versus last year, helped by lower selling, general and administrative expenses and steady gross margins around the low‑30% range. Basic and diluted earnings per share were $0.010 for the quarter and $0.012 year‑to‑date.
The balance sheet remained conservative, with total assets of $11.5 million, including $1.8 million in cash and $6.7 million in marketable U.S. Treasury securities. Working capital was about $10.2 million, even after paying a $0.075 per share cash dividend totaling $1.72 million and repurchasing a small number of shares. Management believes existing liquidity and cash generation are sufficient to fund operations and its stock repurchase program.
Pharma-Bio Serv, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders elected Irving Wiesen as a Class I director to serve until the 2029 Annual Meeting, with 10,208,071 votes for and 195,625 votes withheld, plus 2,839,645 broker non-votes. Stockholders also ratified the selection of Crowe PR PSC as independent certified public accountants for the fiscal year ending October 31, 2026, with 13,241,794 votes for, 3 against and 1,544 abstentions.
Pharma-Bio Serv, Inc. reports its Annual Report on Form 10-K for the fiscal year ended October 31, 2025, detailing operations as a technical compliance and regulatory consulting firm serving Puerto Rico, the United States, Europe and Brazil. Revenue was $9.0M for the year, with a net loss of $(0.1M) (loss per share $0.004). Gross profit margin improved to 32.3% from 26.5%, driven by higher-margin work in Europe. Working capital was approximately $11.6M, shares outstanding were 22,904,492 as of January 23, 2026, and aggregate market value held by non-affiliates was $6,136,220 as of April 30, 2025.
Pharma-Bio Serv, Inc. is holding its 2026 Annual Meeting on May 15, 2026 in Boca Raton, Florida to elect one Class I director and ratify its independent auditor. Stockholders of record at the close of business on April 8, 2026, when 22,901,692 shares of common stock were outstanding, may vote.
The Board proposes re-electing long‑time director Irving Wiesen to a term running through the 2029 meeting and ratifying Crowe PR PSC as auditor for the year ending October 31, 2026. All four directors are deemed independent under Nasdaq standards, and committee structures for audit, compensation, nominating/governance, and M&A are described.
The proxy details 2025 director retainers of $50,000 plus annual option grants of 20,000 shares, and executive salaries including $231,000 for CEO Victor Sanchez and $175,000 for CFO Pedro Lasanta. Audit, audit‑related and other fees to Crowe totaled $113,740 in fiscal 2025. Procedures for attending, registering, submitting proposals, and nominating directors in future years are also outlined.
Pharma-Bio Serv reported revenues of approximately $2.3 million for the quarter ended January 31, 2026, a decrease of about $0.2 million from the same period last year. Despite lower sales, the company posted net income of $32,860, an improvement of $24,324 compared with a slight loss a year earlier.
Management highlighted ongoing efforts to sharpen the service portfolio, reinforce operational alignment, and focus on markets where its consulting capabilities add the most value. The CEO stated that improved operational efficiency supported the return to profit and expressed confidence in building momentum through stronger client relationships and disciplined cost management.
Pharma-Bio Serv, Inc. reported nearly flat operations but remained profitable for the quarter ended January 31, 2026. Revenue was about $2.3 million, down from $2.5 million a year earlier, as U.S. and Europe consulting projects declined while Puerto Rico inched up.
Gross margin was stable at 31.5%, with a small operating loss of $94,535 offset by $131,025 of other income, mainly interest and foreign exchange gains, yielding net income of $32,860. Earnings per share were effectively breakeven at $0.001.
The company ended the quarter with $5.8 million in cash and $4.8 million in marketable U.S. Treasury securities, and working capital of about $10 million. It declared a $0.075 per-share cash dividend (about $1.72 million) and repurchased 3,100 shares at $0.54. Headquarters moved to a virtual model after its only long-term lease expired, and management believes existing resources are sufficient to fund operations beyond the next twelve months.
Pharma-Bio Serv, Inc. filed Amendment No. 1 to its annual report for the year ended October 31, 2025 to add updated Part III information on governance, compensation, ownership and auditor matters. The amendment does not change the previously reported financial results and is meant to be read together with the original Form 10-K.
The filing details a four‑member, fully independent board under Nasdaq standards, with standing audit, compensation, and nominating committees. It describes long‑tenured CEO Victor Sanchez and CFO Pedro Lasanta, whose salaries in fiscal 2025 were $231,000 and $175,000, respectively, with only statutory bonuses and limited perquisites.
Independent directors each received $50,000 in cash fees plus stock options. The company discloses a related‑party AI Agreement: for $250,000 it obtained an AI‑based lead generation platform, a 2.44% interest in an AI company and an option to raise that interest to 16.67%. Crowe PR PSC billed $113,740 in audit and related services for 2025, all pre‑approved by the audit committee.
Pharma-Bio Serv, Inc. reported that it has released its financial results for the year ended October 31, 2025. The company announced these full-year results through a press release dated January 29, 2026, which is attached to this report as Exhibit 99.1.
The filing emphasizes that the press release and related financial information are being furnished rather than filed, meaning they are not automatically incorporated into other securities filings unless specifically referenced.
Pharma-Bio Serv, Inc. reports results for the year ended October 31, 2025, highlighting a small net loss and stronger margins in its global compliance consulting business. Revenue was about $9.0 million, down from $9.5 million, as growth in Europe was offset by softer demand in Puerto Rico, the United States and Brazil.
Gross profit margin improved to 32.3% from 26.5% as project mix and pricing boosted profitability, reducing the net loss to roughly $0.1 million from $0.8 million. Three major customers provided 43.5% of revenue, underscoring client concentration risk. Working capital of about $11.6 million supports operations, dividends and buybacks.
The company paid a $0.075 per share cash dividend and repurchased shares under its ongoing program, while shifting to a fully remote structure except for a small Madrid office. It also holds a $6.7 million judgment against a customer, though collection remains uncertain. Management cites tax changes, Puerto Rico economic conditions, industry consolidation and cybersecurity as key risks.